Minocycline is a semisynthetic derivative of tetracycline with improved tissue adsorption into the central nervous system (CNS) and with a longer half-life. In addition to its antibiotic activity, minocycline has anti-inflammatory and antiapoptotic activities and is effective in delaying disease progression in numerous models of neurodegeneration.
1 Visual images focused on the retina are sensed by rod and cone photoreceptors. Owing to their high content of mitochondria, photosensitizers, and pigments; high metabolic rates; and rapid responses to small changes in light, photoreceptors are particularly susceptible to excessive exposure to light and oxygen,
2 3 4 5 6 7 8 and they are the first retinal cell type to show signs of damage after light-induced stress.
9 Minocycline has been found to be protective of photoreceptors from light-induced damage in BALB/cJ mice and in rats.
10 11 It also delays photoreceptors degeneration in the
rds mouse, which is homozygous for the null mutation of the gene peripherin 2, which is essential for the formation and maintenance of normal photoreceptor outer segments.
12 Based on the reduction of immunolabeling of CD11b of microglial cells found in the retina, it has been suggested that minocycline may protect against light-induced loss of photoreceptors indirectly, through the inhibition of retinal microglial activation.
10 This hypothesis is consistent with the finding that conditioned medium from activated microglial cells can induce apoptosis in a transformed photoreceptor cell line, 661W.
13 14 Based on its anti-inflammatory activity, minocycline has been suggested for the treatment of age-related macular degeneration (AMD).
15 An earlier study,
12 however, indicated that the delay of photoreceptor death by minocycline is independent of the reduction of microglial cells in the retina, as depletion of microglial cells using liposomal clodronate instead of minocycline showed no protection of photoreceptor apoptosis in the
rds mouse model. Although there are promising results of minocycline as a neuroprotective agent, it has also been shown to have variable or even contradictory results in different models of neurodegeneration in different species.
16 17 18 19 20 To determine whether minocycline can protect photoreceptors in an in vitro system derived from primary retinal cell culture, we studied the effect of minocycline and its analogues on light or tertiary butyl hydroperoxide (tBOOH)–induced damage of photoreceptors in bovine primary retinal cell cultures.